^
    Back
    Association details:
    Biomarker:ER positive
    Cancer:HER2 Negative Breast Cancer
    Drug:imlunestrant (LY3484356) (Selective estrogen receptor degrader)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: C3 – Early Trials
    New
    Source:
    ESMO 2023
    Title:

    383MO - Imlunestrant with or without everolimus or alpelisib, in ER+, HER2- advanced breast cancer (aBC): Results from the phase Ia/b EMBER study

    Published date:
    10/16/2023
    Excerpt:
    Imlunestrant alone or in combination with everolimus or alpelisib demonstrated robust efficacy in pts with pre-treated ER+, HER-2 aBC.
    Trial ID:
    EMBER
    Evidence Level:
    Sensitive: C3 – Early Trials
    Source:
    ASCO 2021
    Title:

    A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.

    Published date:
    05/19/2021
    Excerpt:
    Phase 1a evaluated LY3484356 dose escalation (i3+3 design) in women with ER+, HER2- Abc...Among 16 evaluable pts, 11 (8 aBC, 3 EEC) had stable disease...LY3484356 QD dosing shows favorable safety and PK properties, along with preliminary efficacy in pts with heavily pretreated ER+ aBC and EEC.
    DOI:
    10.1200/JCO.2021.39.15_suppl.1050
    Trial ID:
    EMBER